LION bioscience Reaches Major Milestone in Collaboration with Bayer AG For the Identification and Validation of Drug Targets

LION Provides Complete Knowledge Management Infrastructure to

Analyze and Interpret Human Genome Data



Apr 05, 2001, 01:00 ET from LION bioscience

    HEIDELBERG, Germany, April 5 /PRNewswire Interactive Release/ --
 LION bioscience AG (Nasdaq:   LEON; Neuer Markt: LIO, WKN 504 350) announced
 today that it has identified 250 targets for Bayer AG (Dax: BAY) after only
 22 months, half of the agreed time frame, putting the partnership 20 months
 ahead of schedule.  Additionally, over 250 patents have been filed,
 150 targets have been progressed into future development and one target has
 moved into pre-clinical development.  Under terms of the agreement, LION will
 receive royalties on drugs developed with gene targets identified and
 validated.  This progress demonstrates a clear improvement in discovery
 efficiency through the application of LION's integrated knowledge management
 solution i-biology(R) and confirms the potency of LION's solutions for Life
 Science research under competitive conditions.
     "We are pleased that LION has exceeded our expectations in the delivery of
 therapeutic targets," said Prof. Wolfgang Hartwig, Executive Vice President of
 International Pharma Research at Bayer, and Chairman of the company's Life
 Science Research Committee.  "Our partnership with LION has significantly
 increased our number of targets which we can now proceed into the next steps.
 Together with the targets from our other partners this will increase our
 output performance and cost efficiency while reducing our overall
 target-to-development cycle time."
     The five-year collaboration with Bayer AG was initiated in 1999 for the
 establishment of an information technology-based (IT) knowledge management
 system and its application for in silico identification and validation of new
 drug targets, gene expression markers and single nucleotide polymorphisms
 (SNPs).  The collaboration was valued at $100 million and included the
 formation of a new research subsidiary, LION bioscience Research, Inc. In
 October 2000 this i-biology(R) collaboration was extended into the field of
 pharmacophore informatics, pioneering the link between biology and chemistry,
 to identify the relevant biological and chemical structural elements
 responsible for the success of a compound derived from the increasing amounts
 of structures that are being delivered by today's numerous high-throughput
 systems.
     "We are proud to have provided Bayer with 250 targets in nearly half the
 agreed time," said Dr. Friedrich von Bohlen, CEO of LION bioscience AG.  "At
 the same time, we have built a worldwide R&D information management system to
 support and integrate its global discovery activities.  The success of
 partners like Bayer further establishes our solutions as the standard for
 integrated information and knowledge management in the Life Sciences
 Industry."
 
     About LION bioscience AG:
     LION bioscience (http://www.lionbioscience.com) provides proven
 information and knowledge management solutions to significantly improve life
 science R&D performance and productivity.  These solutions integrate all R&D
 disciplines, spanning from genetics to early and late discovery through
 clinical trials.  LION offers these solutions via two primary lines of
 business:
     * i-biology(R): the installation and implementation of enterprise-wide
       horizontal information and knowledge management solutions as part of
       LION's Life Science Informatics (LSI(TM)) line of business; and
     * Integrated Drug Discovery and Diagnostics (iD3(TM)): application of
       i-biology(R) to LION's internal drug discovery program with the goal to
       out-license specific databases, polymorphism marker panels, and
       validated targets and leads.
 
     Founded in 1997, LION, together with its consolidated subsidiaries, has
 more than 440 employees, with headquarters in Heidelberg, Germany, and
 subsidiaries in Cambridge, UK, Cambridge, MA, USA, and as a result of the
 Trega acquisition, San Diego, CA, USA.  To date, LION has established
 partnerships with leading life science companies, including Aventis, Bayer,
 Boehringer Ingelheim, Celera, DuPont, Glaxo Wellcome, GMD, Janssen, Merck
 Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche,
 SmithKline Beecham, Sumitomo Pharmaceuticals and Tripos.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the U.S. securities laws.
 Such statements are based on current expectations that are subject to risks
 and uncertainties.  Actual results may vary materially from those projected
 because of factors such as uncertainties relating to technologies, product
 development, or manufacturing, market acceptance, cost or pricing of LION's
 products, dependence on collaborations and partners, regulatory approvals,
 competition, intellectual property of others, or patent protection and
 litigation.  These and other risk factors are discussed in LION's Registration
 Statement on Form F-4 declared effective by the SEC on February 9, 2001.  LION
 expressly disclaims any obligation or undertaking to release publicly any
 updates, revisions or corrections to any forward-looking statements or
 historical information contained herein.
 
     LION bioscience(R), SRS, SRS 6.1 and i-biology(R) are either registered
 trademarks of LION bioscience AG in the United States and/or other countries,
 or LION bioscience AG has pending applications for these trademarks in the
 United States and/or other countries.  The names of other actual companies and
 products mentioned herein may be the trademark of their respective owners.
 Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in
 the United States.  Trega(R) is a registered trademark of Trega Biosciences,
 Inc.
 
     CONTACT:
 
     Noonan/Russo Communications      LION bioscience
     Matthew Scampoli                 Dr. Andrea Kreisselmeier
     +1 212-696-4455 ext. 243         Dir. Corporate Marketing & Communications
     m.scampoli@noonanrusso.com       +49 (0)6221-4038 265
                                      andrea.kreisselmeier@lionbioscience.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
             http://tbutton.prnewswire.com/prns.jsp?11690X08520587
 
 

SOURCE LION bioscience
    HEIDELBERG, Germany, April 5 /PRNewswire Interactive Release/ --
 LION bioscience AG (Nasdaq:   LEON; Neuer Markt: LIO, WKN 504 350) announced
 today that it has identified 250 targets for Bayer AG (Dax: BAY) after only
 22 months, half of the agreed time frame, putting the partnership 20 months
 ahead of schedule.  Additionally, over 250 patents have been filed,
 150 targets have been progressed into future development and one target has
 moved into pre-clinical development.  Under terms of the agreement, LION will
 receive royalties on drugs developed with gene targets identified and
 validated.  This progress demonstrates a clear improvement in discovery
 efficiency through the application of LION's integrated knowledge management
 solution i-biology(R) and confirms the potency of LION's solutions for Life
 Science research under competitive conditions.
     "We are pleased that LION has exceeded our expectations in the delivery of
 therapeutic targets," said Prof. Wolfgang Hartwig, Executive Vice President of
 International Pharma Research at Bayer, and Chairman of the company's Life
 Science Research Committee.  "Our partnership with LION has significantly
 increased our number of targets which we can now proceed into the next steps.
 Together with the targets from our other partners this will increase our
 output performance and cost efficiency while reducing our overall
 target-to-development cycle time."
     The five-year collaboration with Bayer AG was initiated in 1999 for the
 establishment of an information technology-based (IT) knowledge management
 system and its application for in silico identification and validation of new
 drug targets, gene expression markers and single nucleotide polymorphisms
 (SNPs).  The collaboration was valued at $100 million and included the
 formation of a new research subsidiary, LION bioscience Research, Inc. In
 October 2000 this i-biology(R) collaboration was extended into the field of
 pharmacophore informatics, pioneering the link between biology and chemistry,
 to identify the relevant biological and chemical structural elements
 responsible for the success of a compound derived from the increasing amounts
 of structures that are being delivered by today's numerous high-throughput
 systems.
     "We are proud to have provided Bayer with 250 targets in nearly half the
 agreed time," said Dr. Friedrich von Bohlen, CEO of LION bioscience AG.  "At
 the same time, we have built a worldwide R&D information management system to
 support and integrate its global discovery activities.  The success of
 partners like Bayer further establishes our solutions as the standard for
 integrated information and knowledge management in the Life Sciences
 Industry."
 
     About LION bioscience AG:
     LION bioscience (http://www.lionbioscience.com) provides proven
 information and knowledge management solutions to significantly improve life
 science R&D performance and productivity.  These solutions integrate all R&D
 disciplines, spanning from genetics to early and late discovery through
 clinical trials.  LION offers these solutions via two primary lines of
 business:
     * i-biology(R): the installation and implementation of enterprise-wide
       horizontal information and knowledge management solutions as part of
       LION's Life Science Informatics (LSI(TM)) line of business; and
     * Integrated Drug Discovery and Diagnostics (iD3(TM)): application of
       i-biology(R) to LION's internal drug discovery program with the goal to
       out-license specific databases, polymorphism marker panels, and
       validated targets and leads.
 
     Founded in 1997, LION, together with its consolidated subsidiaries, has
 more than 440 employees, with headquarters in Heidelberg, Germany, and
 subsidiaries in Cambridge, UK, Cambridge, MA, USA, and as a result of the
 Trega acquisition, San Diego, CA, USA.  To date, LION has established
 partnerships with leading life science companies, including Aventis, Bayer,
 Boehringer Ingelheim, Celera, DuPont, Glaxo Wellcome, GMD, Janssen, Merck
 Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche,
 SmithKline Beecham, Sumitomo Pharmaceuticals and Tripos.
 
     All statements in this press release that are not historical are
 forward-looking statements within the meaning of the U.S. securities laws.
 Such statements are based on current expectations that are subject to risks
 and uncertainties.  Actual results may vary materially from those projected
 because of factors such as uncertainties relating to technologies, product
 development, or manufacturing, market acceptance, cost or pricing of LION's
 products, dependence on collaborations and partners, regulatory approvals,
 competition, intellectual property of others, or patent protection and
 litigation.  These and other risk factors are discussed in LION's Registration
 Statement on Form F-4 declared effective by the SEC on February 9, 2001.  LION
 expressly disclaims any obligation or undertaking to release publicly any
 updates, revisions or corrections to any forward-looking statements or
 historical information contained herein.
 
     LION bioscience(R), SRS, SRS 6.1 and i-biology(R) are either registered
 trademarks of LION bioscience AG in the United States and/or other countries,
 or LION bioscience AG has pending applications for these trademarks in the
 United States and/or other countries.  The names of other actual companies and
 products mentioned herein may be the trademark of their respective owners.
 Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in
 the United States.  Trega(R) is a registered trademark of Trega Biosciences,
 Inc.
 
     CONTACT:
 
     Noonan/Russo Communications      LION bioscience
     Matthew Scampoli                 Dr. Andrea Kreisselmeier
     +1 212-696-4455 ext. 243         Dir. Corporate Marketing & Communications
     m.scampoli@noonanrusso.com       +49 (0)6221-4038 265
                                      andrea.kreisselmeier@lionbioscience.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
             http://tbutton.prnewswire.com/prns.jsp?11690X08520587
 
 SOURCE  LION bioscience